Introduction
Breast cancer resistance protein (BCRP), encoded by ATP-binding cassette sub-family G member 2 (ABCG2), is a member of the ATP-dependent transporter family that can actively extrude compounds out of cells. BCRP is expressed in many tissues including canalicular membranes of hepatocytes, apical membranes of enterocytes, apical membranes of kidney proximal tubule cells, blood brain barrier endothelium, placenta and lactating mammary gland (Maliepaard et al, 2001; Fetsch et al, 2006) . Substrate specificity of BCRP is broad and includes chemotherapy agents, statins, antibiotics, carcinogens, and sulfate conjugates (Robey et al, 2007) .
BCRP polymorphisms may contribute to inter-individual variability of pharmacokinetics (PK) and BCRP inhibition may lead to drug-drug interactions in the clinic. Single nucleotide polymorphisms (SNP) in the ABCG2 gene are common and vary among ethnic groups, in particular, a non-synonymous 421C>A SNP. This SNP was not detected in African Americans, but 25.9% of European Americans and 50 to 60% of Asian Americans had at least one variant allele (Zamber et al, 2003) . ABCG2 421C>A SNP results in a lysine to glutamine acid change at codon 141 (Q141K), which leads to decreased protein expression level or reduced drug resistance to anti-cancer agents in transfected cells (Imai et al, 2002; Mizuarai et al, 2004; Morisaki et al, 2005; Tamura et al, 2006; Sawada et al, 2007; Furukawa et al, 2009 ). The Q141K variant was associated with increased risk for gefitinib-induced diarrhea (Cusatis et al, 2006) . Oral exposure of sulfasalazine and rosuvastatin in the subjects with ABCG2 421AA genotype was approximately 2 to 3.5-fold higher than in the control subjects (ABCG2 421CC), were used to determine the relative expression and profiling of the selected genes. The selected PCR primers were gene specific and were designed to span an exon-exon junction.
Quantitation of the transcription levels and statistical analysis using the parametric t test were performed as described previously (Tchaparian et al, 2011) . Gene expression values were normalized to the level of 18S rRNA, GAPDH or ß-actin. For each gene, the false discovery rate was estimated and used to determine the corresponding adjusted p value. Only genes exhibiting expression changes at a significant level (adjusted p <0.05, fold change of 2) were considered to be differentially expressed.
Cyp3a activity in the pooled liver microsomes was measured by testosterone 6ß-hydroxylation (Anderson et al, 1998 fetal bovine serum and hygromycin B (500 µg/mL), a selection agent for the vector.
Transport studies were conducted in 24-well transwell plates (duplicate or triplicate) according to the method described previously (Huang et al, 2010 ) with some modification. Briefly, compounds were tested at 5 µM in the incubation buffer (Hanks balance salt solution containing 0.1% bovine serum albumin) 5 days post seeding.
Transport studies were conducted at 37 °C in the air with shaking (60 rpm) for 120 min
For quantification of test compounds in the samples, calibration curve standards (ranged from 0.001 to 1 µM) were prepared from the 5 µM incubation solution. Aliquots from the apical receiver and donor chambers were diluted 2-, and 5-fold with the incubation buffer, respectively. A mixture containing 0.1% formic acid, 66.6% acetonitrile and 33.3% water was added to samples at 4:1 ratio to precipitate protein.
Samples were analyzed as described in the section of liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis. Detection limit ranged from 0.001 to 0.037 µM.
The apparent permeability (Papp), and efflux ratios were calculated according to the following equations (Huang et al, 2010) :
Efflux Ratio=Papp B→A / Papp A→B .
where A is the membrane surface area, C 0 is the donor drug concentration at t = 0, dQ/dt is the amount of drug transported within a given time period. Papp B→A and Papp A→B are the Papp values in the basolateral to apical and apical to basolateral direction, respectively. For Papp of <1x10 -6 cm/s, specific values were not reported in consideration of LC-MS/MS detection sensitivity and variability.
Biliary Excretion and Urinary Excretion Study Following IV Administration
Rats were anesthetized with ketamine (30 mg/kg) and dexmedetomidine (0.2 mg/kg) administered by intramuscular injection. The left femoral vein and artery were catheterized for compound administration and blood collection, respectively. Silastic catheters were implanted in the bile duct for bile collection and in the proximal duodenum for bile circulation and infusion of replacement fluids. The catheters were protected by a Covance infusion harness and were connected to permit bile recirculation. The rats were housed in metabolic cages throughout the experiment for collection of excreta.
Following a recovery period of 2 to 3 days, rats were administered a single dose of test material by bolus injection into the femoral vein catheter and the catheter was flushed with saline to ensure full delivery of the dose. Bile samples were collected from 0 to 0.5, 0.5 to 1, 1 to 2, 2 to 4, 4 to 6, and 6 to 8, and 8-24 hr (digoxin at 0.25 mg/kg, sulfasalazine and compound A at 1 mg/kg) or 0 to 0.5, 0.5 to 1, 1 to 2, 2 to 4, 4 to 8, and 8-24 hr (nitrofurantoin and compound A at 5 mg/kg). Urine samples were collected from This article has not been copyedited and formatted. The final version may differ from this version.
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LC-MS/MS Analysis
The LC-MS/MS system consisted of two LC-10AD HPLC pumps and a DGU-14A degasser (Shimadzu, Columbia, MD), a CTC PAL autoinjector (Leap Technologies, Carrboro, NC), and an API4000 mass spectrometer (Applied Biosystems, Foster City, CA). Samples from in vitro experiments were injected onto a Sprite Armor C18
analytical column (20 mm × 2.1 mm, 10 µm pore size; Analytical Sales and Products, Pompton Plains, NJ) with a 0.5 µm polyether ether ketone guard filter. Analytes were separated using a gradient solvent system consisting of solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid in acetonitrile) at a flow rate of 0.4 mL/min. The percentage of solvent B was increased in a linear fashion from 2 to 95% over 2 min.
Drug concentrations in extracted samples from in vivo studies were determined using reversed-phase liquid chromatography with a solvent system consisting of solvent A (0.1% formic acid in water) and solvent B (acetonitrile containing 0.1% formic acid) at a flow rate of 0.55 mL/min. Samples were injected onto a Varian Pursuit C18 column (30x2mm, 5 µm pore size) and were separated using a gradient with linear increase of solvent B from 10 to 90% with a total run time of 2.5 min for each sample. LC-MS/MS analysis was performed using atmospheric pressure chemical ionization and multiple reactions monitoring in the positive ion mode.
In Vitro Transport of Digoxin, Sulfasalazine, Nitrofurantoin and Compound A Table 2) .
Excretion and PK parameters of Digoxin in Abcg2(-/-) and Abcg2(+/+) Rats
Digoxin was used as a probe substrate to assess Pgp activity in vivo. Approximately 6% and 20% of the dose was excreted into bile and urine as parent, in either the
Renal CL in the Abcg2(-/-) rats was unaffected for nitrofurantoin and compound A, but was decreased by more than 90% for sulfasalazine (Table 4) .
Plasma Pharmacokinetics in Bile Duct Intact Rats Following IV and Oral Administration
To assess the effect of Bcrp on CL, IV PK studies were conducted for the three probe substrates in bile duct intact rats. Systemic plasma CL was unaffected for nitrofurantoin, but decreased significantly (40%, P<0.05) for sulfasalazine in the Abcg2(-/-) rats compared with the Abcg2(+/+) rats (Table 5 ). IV PK of compound A was assessed at two doses (1 and 5 mg/kg). The absence of Bcrp led to a 2.6-fold increase in the systemic exposure of compound A at 1 mg/kg, but had no effect on its exposure at 5 mg/kg (Figure 3 ). In the Abcg2(+/+) rats, CL of compound A decreased from 2.7 L/hr/kg to 1.1 L/hr/kg (P<0.01, unpaired t-test between the 1 and 5 mg/kg dose group) when the dose was increased from 1 mg/kg to 5 mg/kg. In contrast, CL in the Abcg2(-/-) rats was dose-independent (Table 5) .
Following oral administration, nitrofurantoin was well absorbed, exhibiting comparable oral bioavailability between the Abcg2(+/+) and the Abcg2(-/-) rats (Table 6 , Figure 4 ).
In contrast, AUC 0-inf , C max and F in the Abcg2(-/-) rats increased 33-, 21-and 17-fold, respectively, for sulfasalazine and 10-, 5-and 4-fold, respectively, for compound A.
However, oral bioavailability of sulfasalazine and compound A remained low in the Abcg2(-/-) rats. The T max of sulfasalazine increased in the Abcg2(-/-) rats (Table 6 ). ± 5.8 mL/24 hr, n=17) and Abcg2(-/-) rats (24.5 ± 6.5 mL/24 hr, n=17), as opposed to decreased bile flow in multiple drug resistance protein 2 deficient rats (Huang et al, 2000) . These data suggest that Abcg2(-/-) rats have an appropriate degree of selectivity for assessing the contribution of Bcrp transport to excretion and CL.
Nitrofurantoin, sulfasalazine, and compound A were selected as BCRP probe substrates for in vivo evaluation because of their different characteristics in terms of permeability, Pgp, and BCRP substrate status. Nitrofurantoin exhibits good permeability and is a substrate for BCRP, but not for Pgp (Merino et al, 2005) . This article has not been copyedited and formatted. The final version may differ from this version.
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